New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
15:57 EDTKYTHKythera announces positive interim results from SMF study
KYTHERA Biopharmaceuticals announced positive interim results from a Phase IIIb, multi-center, open-label study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, SMF, commonly known as double chin. The results, presented at the Late Breaking Research Symposium at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla., found that ATX-101 is well-tolerated and may be effective in reducing SMF by both clinician and patient reported outcome measures. The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
16:46 EDTKYTHAllergan, KYTHERA announce early termination of HSR waiting period
Subscribe for More Information
09:03 EDTKYTHKYTHERA announces Health Canada authorization of Belkyra
KYTHERA Biopharmaceuticals announced it has received authorization from Health Canada to market Belkyra "for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.” Belkyra is a non-surgical treatment for improving the appearance and profile of submental fullness—more commonly known as “double chin,” a facial aesthetic condition that affects both women and men. Belkyra was recently launched in the U.S. under the brand name Kybella.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use